It is now evident that the commonly accepted strategy for treatment of HIV/AIDS by highly active antiretroviral therapy (HAART) will not lead to eradication of HIV in a reasonable time. This is straightforward from the typical exponential viral load decay upon treatment revealing initial considerable but incomplete reduction of plasma HIV RNA with subsequent low level HIV persistence even in patients on effective antiretroviral therapy. Here we show that the viral load follows a simple zero trend linear regression line under different treatment approach recently proposed by us. This unambiguously indicates a whole body HIV eradication in reasonable time.
Antimicrobial biomaterials are critical to aid in the regeneration of oral soft tissue and prevent or treat localised bacterial infections. With the rising trend in antibiotic resistance, there is a pressing clinical need for new antimicrobial chemistries and biomaterial design approaches enabling on-demand activation of antibiotic-free antimicrobial functionality following an infection that are environment-friendly, flexible and commercially-viable. This study explores the feasibility of integrating a bioresorbable electrospun polymer scaffold with localised antimicrobial photodynamic therapy (aPDT) capability. To enable aPDT, we encapsulated a photosensitiser (PS) in polyester fibres in the PS inert state, so that the antibacterial function would be activated on-demand via a visible light source. Fibrous scaffolds were successfully electrospun from FDA-approved polyesters, either poly(epsilon-caprolactone (PCL) or poly[(rac-lactide)-co-glycolide] (PLGA) with encapsulated PS (either methylene blue (MB) or erythrosin B (ER)). The electrospun fibres achieved an ~100 wt.% loading efficiency of PS, which significantly increased their tensile modulus and reduced their average fibre diameter and pore size with respect to PS-free controls. In vitro, PS release varied between a burst release profile to limited release within 100 hours depending on the selected scaffold formulation. Exposure of PS-encapsulated PCL fibres to visible light successfully led to at least a 1 log reduction in E. coli viability after 60 minutes of light exposure whereas PS-free electrospun controls did not inactive microbes. This study successfully demonstrates the significant potential of PS-encapsulated electrospun fibres as photodynamically active biomaterial for antibiotic-free infection control.
The human aorta is a high-risk area for vascular diseases, which are commonly restored by thoracic endovascular aortic repair. In this paper, we report a promising shear-activated targeted nanoparticle drug delivery strategy to assist in the treatment of coarctation of the aorta and aortic aneurysm. Idealized three-dimensional geometric models of coarctation of the aorta and aortic aneurysm are designed, respectively. The unique hemodynamic environment of the diseased aorta is used to improve nanoparticle drug delivery. Micro-carriers with nanoparticle drugs would be targeting activated to release nanoparticle drugs by local abnormal shear stress rate (SSR). Coarctation of the aorta provides a high SSR hemodynamic environment, while the aortic aneurysm is exposed to low SSR. Results show that the upstream near-wall area of the diseased location is an ideal injection point for the micro-carriers, which could be activated by the abnormal SSR. Released nanoparticle drugs would be successfully targeted delivered to the aortic diseased wall. Besides, coarctation of the aorta would prevent blood flow to the descending aorta, while the effect of the aortic aneurysm on the blood flow distribution is negligible. This study preliminary demonstrates the feasibility of shear-activated targeted nanoparticle drug delivery in the treatment of aortic diseases and provides a theoretical basis for developing novel therapy.
HIV-1 can disseminate between susceptible cells by two mechanisms: cell-free infection following fluid-phase diffusion of virions and by highly-efficient direct cell-to-cell transmission at immune cell contacts. The contribution of this hybrid spreading mechanism, which is also a characteristic of some important computer worm outbreaks, to HIV-1 progression in vivo remains unknown. Here we present a new mathematical model that explicitly incorporates the ability of HIV-1 to use hybrid spreading mechanisms and evaluate the consequences for HIV-1 pathogenenesis. The model captures the major phases of the HIV-1 infection course of a cohort of treatment naive patients and also accurately predicts the results of the Short Pulse Anti-Retroviral Therapy at Seroconversion (SPARTAC) trial. Using this model we find that hybrid spreading is critical to seed and establish infection, and that cell-to-cell spread and increased CD4+ T cell activation are important for HIV-1 progression. Notably, the model predicts that cell-to-cell spread becomes increasingly effective as infection progresses and thus may present a considerable treatment barrier. Deriving predictions of various treatments influence on HIV-1 progression highlights the importance of earlier intervention and suggests that treatments effectively targeting cell-to-cell HIV-1 spread can delay progression to AIDS. This study suggests that hybrid spreading is a fundamental feature of HIV infection, and provides the mathematical framework incorporating this feature with which to evaluate future therapeutic strategies.
Brain tumours are masses of abnormal cells that can grow in an uncontrolled way in the brain. There are different types of malignant brain tumours. Gliomas are malignant brain tumours that grow from glial cells and are identified as astrocytoma, oligodendroglioma, and ependymoma. We study a mathematical model that describes glia-neuron interaction, glioma, and chemotherapeutic agent. In this work, we consider drug sensitive and resistant glioma cells. We show that continuous and pulsed chemotherapy can kill glioma cells with a minimal loss of neurons.
E. E. Gabev
.
(2007)
.
"Fitting analysis provides further evidence for eradication of hiv/aids infection under combined liposome drug delivery treatment"
.
Evgeni Gabev E
هل ترغب بارسال اشعارات عن اخر التحديثات في شمرا-اكاديميا